@Article{,
AUTHOR = {Laurence H. Klotz},
TITLE = {PSA recurrence: definitions, PSA kinetics, and identifying patients at risk},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {13},
YEAR = {2006},
NUMBER = {Suppl.2},
PAGES = {43--47},
URL = {http://www.techscience.com/CJU/v13nSuppl.2/63353},
ISSN = {1488-5581},
ABSTRACT = {Uncertainty exists for clinicians and patients with respect
to choosing the optimal therapy for patients with PSA
recurrence. There is no consensus as to what the PSA
cutpoint should be to define PSA failure after radical
prostatectomy (RP) or radiation therapy (XRT). We do,
however, have validated nomograms which allow the
stratification of patients according to their risk of disease
progression and cancer specific death. This is based in
large part on PSA kinetics. A short PSA doubling time
(PSA-DT) is associated with a marked increase in the
risk of prostate cancer death in the 5-10 year time frame.
PSA DT can also be used to identify patients most likely
to respond to local salvage therapy.},
DOI = {}
}